Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,512 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mannitol versus furosemide in patients with thoracic malignancies who received cisplatin-based chemotherapy using short hydration: A randomized phase II trial.
Murakami E, Akamatsu H, Teraoka S, Takakura T, Takase E, Tanaka M, Kaki T, Harutani Y, Furuta K, Sugimoto T, Shibaki R, Fujimoto D, Hayata A, Ozawa Y, Nakanishi M, Koh Y, Shimokawa T, Yamamoto N. Murakami E, et al. Among authors: sugimoto t. Cancer Med. 2024 Feb;13(4):e6839. doi: 10.1002/cam4.6839. Cancer Med. 2024. PMID: 38457231 Free PMC article. Clinical Trial.
Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer.
Akamatsu H, Murakami E, Oyanagi J, Shibaki R, Kaki T, Takase E, Tanaka M, Harutani Y, Yamagata N, Okuda Y, Furuta K, Sugimoto T, Teraoka S, Hayata A, Tokudome N, Ozawa Y, Mori K, Koh Y, Yamamoto N. Akamatsu H, et al. Among authors: sugimoto t. Oncologist. 2020 Apr;25(4):e679-e683. doi: 10.1634/theoncologist.2019-0299. Epub 2019 Nov 19. Oncologist. 2020. PMID: 32297443 Free PMC article.
CD24, not CD47, negatively impacts upon response to PD-1/L1 inhibitors in non-small-cell lung cancer with PD-L1 tumor proportion score < 50.
Ozawa Y, Harutani Y, Oyanagi J, Akamatsu H, Murakami E, Shibaki R, Hayata A, Sugimoto T, Tanaka M, Takakura T, Furuta K, Okuda Y, Sato K, Teraoka S, Ueda H, Tokudome N, Kitamura Y, Fukuoka J, Nakanishi M, Koh Y, Yamamoto N. Ozawa Y, et al. Among authors: sugimoto t. Cancer Sci. 2021 Jan;112(1):72-80. doi: 10.1111/cas.14705. Epub 2020 Nov 27. Cancer Sci. 2021. PMID: 33084148 Free PMC article.
Impact of pre-existing interstitial lung abnormal shadow on lung injury development and severity in patients of non-small cell lung cancer treated with osimertinib.
Shibaki R, Ozawa Y, Noguchi S, Murakami Y, Takase E, Azuma Y, Maebeya M, Sugimoto T, Hayata A, Hayakawa T, Tamaki S, Nakanishi M, Teraoka S, Akamatsu H. Shibaki R, et al. Among authors: sugimoto t. Cancer Med. 2022 Oct;11(20):3743-3750. doi: 10.1002/cam4.4750. Epub 2022 Apr 17. Cancer Med. 2022. PMID: 35434933 Free PMC article.
A Phase II Study of High-Flow Nasal Cannula for Relieving Dyspnea in Advanced Cancer Patients.
Takase E, Akamatsu H, Teraoka S, Nakaguchi K, Tanaka M, Kaki T, Furuta K, Sato K, Murakami E, Sugimoto T, Shibaki R, Fujimoto D, Hayata A, Tokudome N, Ozawa Y, Koh Y, Nakanishi M, Kanai K, Shimokawa T, Yamamoto N. Takase E, et al. Among authors: sugimoto t. J Pain Symptom Manage. 2024 Mar;67(3):204-211.e1. doi: 10.1016/j.jpainsymman.2023.11.009. Epub 2023 Nov 21. J Pain Symptom Manage. 2024. PMID: 37992848 Free article. Clinical Trial.
Pre-treatment serum protein levels predict survival of non-small cell lung cancer patients without durable clinical benefit by PD-1/L1 inhibitors.
Harutani Y, Ozawa Y, Murakami E, Sato K, Oyanagi J, Akamatsu H, Yoshikawa T, Shibaki R, Sugimoto T, Furuta K, Teraoka S, Tokudome N, Hayata A, Ueda H, Nakanishi M, Koh Y, Yamamoto N. Harutani Y, et al. Among authors: sugimoto t. Cancer Immunol Immunother. 2022 Sep;71(9):2109-2116. doi: 10.1007/s00262-022-03141-4. Epub 2022 Jan 16. Cancer Immunol Immunother. 2022. PMID: 35037070 Free PMC article.
Histologic transformation of epidermal growth factor receptor-mutated lung cancer.
Fujimoto D, Akamatsu H, Morimoto T, Wakuda K, Sato Y, Kawa Y, Yokoyama T, Tamiya M, Hiraoka R, Shingu N, Ikeda H, Tamiya A, Kanazu M, Miyauchi E, Miura S, Yanai M, Yomota M, Morinaga R, Yokoi T, Hata A, Suzuki H, Matsumoto H, Sakata S, Furuya N, Harutani Y, Nakachi I, Otsuki A, Uematsu S, Hara S, Yokoo K, Sugimoto T, Yamamoto N. Fujimoto D, et al. Among authors: sugimoto t. Eur J Cancer. 2022 May;166:41-50. doi: 10.1016/j.ejca.2022.02.006. Epub 2022 Mar 9. Eur J Cancer. 2022. PMID: 35278824
3,512 results